APO-GALANTAMINE MR galantamine (as hydrobromide) 16 mg modified release capsules blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-galantamine mr galantamine (as hydrobromide) 16 mg modified release capsules blister pack

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: iron oxide red; hypromellose; titanium dioxide; magnesium stearate; microcrystalline cellulose; ethylcellulose; gelatin - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

APO-GALANTAMINE MR galantamine (as hydrobromide) 24 mg modified release capsules blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-galantamine mr galantamine (as hydrobromide) 24 mg modified release capsules blister pack

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: erythrosine; ethylcellulose; titanium dioxide; iron oxide yellow; hypromellose; magnesium stearate; iron oxide red; gelatin; microcrystalline cellulose; indigo carmine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

APO-GALANTAMINE MR galantamine (as hydrobromide) 8 mg modified release capsules blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-galantamine mr galantamine (as hydrobromide) 8 mg modified release capsules blister pack

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ethylcellulose; gelatin; magnesium stearate - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Galantamine Oral Solution 4mg/ml Malta - English - Medicines Authority

galantamine oral solution 4mg/ml

rosemont pharmaceuticals limited rosemont house, yorkdale industrial park, braithwaite street, leeds ls11 9xe, united kingdom - galantamine hydrobromide - oral solution - galantamine hydrobromide 4 mg - psychoanaleptics

Galantamine  4mg/ml Oral Solution Malta - English - Medicines Authority

galantamine 4mg/ml oral solution

syri pharma limited floor 0 1 wml, 1 windmill lane dublin 2, d02 f206, ireland - galantamine hydrobromide - oral solution - galantamine hydrobromide 4 mg/ml - psychoanaleptics

GALANTAMINE HYDROBROMIDE capsule, extended release United States - English - NLM (National Library of Medicine)

galantamine hydrobromide capsule, extended release

aphena pharma solutions - tennessee, llc - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 16 mg - galantamine hydrobromide extended-release capsules are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine hydrobromide extended-release capsules are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation.

GALANTAMINE HYDROBROMIDE tablet, film coated United States - English - NLM (National Library of Medicine)

galantamine hydrobromide tablet, film coated

yabao pharmaceutical co., ltd. beijing - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 4 mg - galantamine hydrobromide tablets, usp are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine hydrobromide tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or any excipients used in the formulation. pregnancy category c: there are no adequate and well-controlled studies in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically.  galantamine hydrobromide tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in rats, administration of galantamine (oral doses of 2, 8, or 16 mg/kg/day), from day 14 (females) or day 60 (males) prior to mating and continuing in females through the period of organogenesis, resulted in an increased incidence of fetal ske